Clinical Trial Update: Study of Inhaled RCT1100 in Adults With PCD Caused by Pathogenic Mutations in the DNAI1 Gene to Measure Mucociliary Clearance [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial evaluating inhaled RCT1100 in adults with Primary Ciliary Dyskinesia due to DNAI1 mutations, sponsored by ReCode Therapeutics, currentl…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ciliary Dyskinesia

Drugs mentioned

• RCT1100

Snippet

Sponsor: ReCode Therapeutics | Conditions: Primary Ciliary Dyskinesia (PCD) | Phase 1 | Status: ACTIVE_NOT_RECRUITING